Summary: A groundbreaking study reveals a startling link between cancer suppression and autoimmune disease. Researchers discovered that the immune system can produce antibodies designed to attack tumors that inadvertently target the brain.
Focusing on anti-NMDA receptor encephalitis (ANRE)—the “Brain on Fire” disease—the team found that certain tumors produce NMDA receptors (proteins usually found in the brain). When the immune system evolves potent antibodies to kill these tumor cells, those same antibodies can cross into the brain, causing psychosis and seizures. This “double-edged sword” explains why some cancer patients have better outcomes but suffer neurological “friendly fire.”
Key Facts
- Hidden Triggers: Autoimmune conditions like ANRE may actually be the body’s successful, but collateral, response to a “micro-tumor” the patient never knew they had.
- The NMDA Receptor Bridge: NMDA receptors are critical for brain function, but they are also commonly produced by triple-negative breast cancer cells.
- Protective vs. Harmful: Using cryo-EM imaging, researchers found that the same anti-tumor response produces some antibodies that inhibit brain receptors and others that activate them.
- Clinical Silver Lining: About 15% of triple-negative breast cancer patients had these specific antibodies; notably, these patients had better clinical outcomes, proving the antibodies are effective cancer-killers.
Source: CSHL
Consider two seemingly unrelated medical puzzles. First: Every day, our bodies produce hundreds of billions of new cells, many of which are mutated. If cancer arises from cellular mutation, why don’t we all have the disease all the time? Second: Severe autoimmune conditions like lupus and multiple sclerosis often strike without warning. No one knows what triggers them.
A new study from Cold Spring Harbor Laboratory (CSHL), published in Nature, suggests the two puzzles may be directly connected. The research reveals that our immune system is pre-equipped with antibodies that can both fight tumors and attack the brain.
“Patients with autoimmune diseases often experience the condition coming out of nowhere,” says Sam Kleeman, a recent CSHL Ph.D. graduate, who led the study. “It may be from the cancer you never knew you had.”
Kleeman’s team focused on anti-NMDA receptor encephalitis (ANRE), the debilitating autoimmune brain disease popularized by Susannah Cahalan’s New York Times bestseller Brain on Fire.
In ANRE, the immune system attacks proteins in the brain called NMDA receptors, causing psychosis, insomnia, and seizures. Many patients with this condition are found to have a tumor that produces the same NMDA receptors, but outside the brain.
Using a mouse model of breast cancer, the team traced antibodies from precursors present at birth through their evolution within the tumor into potent cancer-killing molecules. The mice that developed the strongest antibody responses saw their tumors shrink spontaneously. However, when those same antibodies were infused into the brains of healthy mice, they caused seizures and elevated body temperatures, mirroring what patients with ANRE experience.
A key breakthrough came from CSHL Professor Hiro Furukawa, an expert in molecular neuroscience. Using a method called cryo-EM, he realized that some antibodies activated NMDA receptors and others inhibited them.
“This means that the same immune response against a tumor can produce antibodies with completely opposite effects on the brain,” Furukawa explains.
“Understanding which antibodies are harmful and which are protective could eventually help us develop treatments that preserve the immune system’s cancer-fighting abilities while preventing neurological damage.”
With this goal in mind, the team turned their attention to the clinic. Working with Northwell Health, the researchers found that NMDA receptor proteins are commonly produced by tumors in patients with triple-negative breast cancer, a disease known to resist hormone therapy and other common forms of treatment.
About 15% of these patients had formed antibodies targeting NMDA receptors. Notably, these patients tended to have better clinical outcomes, suggesting that their immune systems were actively fighting the cancer.
“With this knowledge, we can now begin carefully designing antibody-based drugs that could one day be used to treat patients with triple-negative breast cancer,” says CSHL Associate Professor Tobias Janowitz, who supervised the study alongside Furukawa.
“Our research shows that while cancer remains deeply puzzling, considering the whole-body response to the disease may help us solve biomedical mysteries that have eluded scientists for decades.”
Key Questions Answered:
A: Yes. The study suggests that some “out of nowhere” autoimmune attacks happen because the immune system successfully found and shrunk a microscopic tumor, but the “soldiers” (antibodies) it created stayed in the system and moved to the brain.
A: Cancer is a master of mutation. Triple-negative breast cancers often “mistakenly” produce NMDA receptors. Because these proteins don’t belong in the breast, the immune system marks them as enemies and attacks.
A: Actually, it’s the opposite. By identifying which antibodies are “the good guys” (killing cancer) and which are “the bad guys” (causing seizures), scientists can design new drugs that target the tumor without touching the brain.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this neurology and cancer news
Author: Samuel Diamond
Source: CSHL
Contact: Samuel Diamond – CSHL
Image: The image is credited to Neuroscience News
Original Research: Open access.
“Ectopic NMDAR expression in cancer unmasks germline-encoded autoimmunity” by Sam O. Kleeman, Kevin Michalski, Xiang Zhao, Ruben Steigerwald, Miriam Ferrer, Llewelyn Levett, Ethan Ertel, Austin Schultz, Noriko Simorowski, Pamela Moody, Tse-Luen Wee, Cristina Valente, Sharon Fox, Mateusz Makuch, Selina Thomsen, Ruby Harrison, Claire Regan, Jonathan Preall, Qing Gao, Dennis Thomas, Jill Habel, Rachel Rubino, Sarosh Irani, Hiro Furukawa & Tobias Janowitz. Nature
DOI:10.1038/s41586-026-10278-0
Abstract
Ectopic NMDAR expression in cancer unmasks germline-encoded autoimmunity
Autoimmunity and anti-cancer immunity lie on the same biological continuum, but their link remains obscure. The paraneoplastic neurological syndrome ANRE (anti-NMDA receptor (NMDAR) encephalitis) is a paradigm for their connectivity, given that intratumoural NMDAR expression is correlated with the generation of anti-NMDAR antibodies.
Here we verify ectopic expression of GluN1 and GluN2B NMDAR subunits in triple-negative breast cancer (TNBC) and model this using orthotopic TNBC tumours with inducible expression of GluN1–GluN2B NMDARs.
We show that NMDAR expression is sufficient to induce the recruitment of B cells and their affinity maturation, consistent with an integrated adaptive immune response.
Reconstruction of extended intratumoural B cell phylogenies and cryogenic electron microscopy structural analyses demonstrate that affinity-matured hypermutated and class-switched antibodies emerged from pre-existing germline-configuration lower-affinity anti-NMDAR antibodies.
Distinct matured antibodies targeted specific epitopes and induced conformational rearrangements within the NMDAR amino-terminal domain, predictive of their functional effects, ranging from inhibition to potentiation.
Passive transfer of an NMDAR-potentiating antibody caused autonomic dysregulation and lowered the seizure threshold in healthy female mice, recapitulating key diagnostic criteria of ANRE.
We further identify a correlation between intratumoural NMDAR expression and anti-NMDAR antibody titres in patients with TNBC. Taken together, our data establish a direct connection between intratumoural NMDAR expression, antibody maturation and the onset of autoimmunity.
These findings suggest that germline-encoded anti-NMDAR antibodies contribute to immune surveillance but can also trigger autoimmune disease after maturation, revealing a mechanistic trade-off between cancer immunity and neurotoxicity.
